Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
16.29
+0.42 (2.65%)
Jun 3, 2026, 12:53 PM EDT - Market open
Viridian Therapeutics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Viridian Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $33.94. The average 1-year stock price forecast is 108.35% higher than the current stock price, while the lowest is $20 (+22.77%) and the highest is $50 (+206.94%).
Price Target: $33.94 (+108.35%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 14 | 14 | 14 | 13 | 13 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 18 | 18 | 18 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Evercore ISI | Evercore ISI | Buy Maintains $27 → $26 | Buy | Maintains | $27 → $26 | +59.61% | May 15, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $48 → $39 | Buy | Maintains | $48 → $39 | +139.41% | May 13, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Maintains $35 | Buy | Maintains | $35 | +114.86% | May 10, 2026 |
| RBC Capital | RBC Capital | Buy Reiterates $30 → $34 | Buy | Reiterates | $30 → $34 | +108.72% | May 6, 2026 |
| Truist Financial | Truist Financial | Buy Maintains $33 → $35 | Buy | Maintains | $33 → $35 | +114.86% | May 6, 2026 |
Financial Forecast
Revenue This Year
33.62M
from 70.85M
Decreased by -52.55%
Revenue Next Year
244.44M
from 33.62M
Increased by 627.09%
EPS This Year
-3.89
from -3.32
EPS Next Year
-2.47
from -3.89
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 66.2M | ||
| Avg | 33.6M | ||
| Low | 10.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -6.6% | ||
| Avg | -52.5% | ||
| Low | -85.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -3.26 | ||
| Avg | -3.89 | ||
| Low | -4.54 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | ||
| Avg | - | ||
| Low | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by S&P Global Market Intelligence. The data is sourced from Wall Street analysts. Data sources.